Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Other financing activities (2016 - 2025)

Historic Other financing activities for Immucell (ICCC) over the last 13 years, with Q2 2025 value amounting to $24905.0.

  • Immucell's Other financing activities fell 8488.79% to $24905.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $84074.0, marking a year-over-year decrease of 6143.47%. This contributed to the annual value of $291834.0 for FY2024, which is 72380.8% up from last year.
  • According to the latest figures from Q2 2025, Immucell's Other financing activities is $24905.0, which was down 8488.79% from $42975.0 recorded in Q1 2025.
  • In the past 5 years, Immucell's Other financing activities registered a high of $164802.0 during Q2 2024, and its lowest value of -$62673.0 during Q4 2023.
  • Moreover, its 5-year median value for Other financing activities was $41382.0 (2022), whereas its average is $52274.1.
  • Within the past 5 years, the most significant YoY rise in Immucell's Other financing activities was 75318.64% (2025), while the steepest drop was 8488.79% (2025).
  • Immucell's Other financing activities (Quarter) stood at $78430.0 in 2021, then crashed by 49.27% to $39789.0 in 2022, then plummeted by 257.51% to -$62673.0 in 2023, then soared by 125.84% to $16194.0 in 2024, then surged by 53.79% to $24905.0 in 2025.
  • Its last three reported values are $24905.0 in Q2 2025, $42975.0 for Q1 2025, and $16194.0 during Q4 2024.